As the second Trump administration settles in, the U.S.' top pharmaceutical trade group is drafting its ambitions for the ...
The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a ...
The meeting, which will include Pfizer CEO Albert Bourla as the newly named board of directors’ chair, will reportedly cover ...
Eli Lilly has unveiled a $27 billion (€25.7 billion) investment in US manufacturing facilities as the pharmaceutical industry ...
House Republicans advanced their budget framework for President Donald Trump’s sweeping domestic policy agenda late Tuesday, ...
Secretary, Measles-dismisser, nepo-baby, bear cub-dumper, and vaccine skeptic, Robert F. Kennedy, Jr., was one of the ...
President Trump also refused to promise pharma execs that he would hamstring the IRA’s drug negotiation program.
The Trump administration, perhaps surprisingly, chose to defend the legality of the Inflation Reduction Act’s (IRA’s) drug ...
A federal judge is refusing to temporarily block the Trump administration’s mass layoff of federal workers while a lawsuit ...
His proposal could prevent pharmacy benefit managers from inflating medication costs by banning spread pricing.
A meeting held between President Donald Trump and top pharmaceutical executives showed some tensions over drug pricing policy, tariffs and manufacturing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results